Darzalex Patient Tips: 7 things you should know Easy-to-read patient tips for Darzalex covering how it works, benefits, risks, and best practices.

#Darzalex is a CD38 monoclonal antibody for Multiple Myeloma, usually given with other treatments by IV infusion. Common side effects include infections, low neutrophils, and infusion reactions. Darzalex Faspro offers a subcutaneous injection alternative.

💊FDA Approval Update | #TECVAYLI (#teclistamab-cqyv) and #DARZALEX FASPRO (#daratumumab and #hyaluronidase-fihj)
🌟For adults with relapsed/refractory multiple myeloma after ≥1 prior therapy
🌟Significantly reduced the risk of disease progression or death
#MultipleMyeloma #Immunotherapy

FDA Grants Approval for TECVAYLI® and DARZALEX FASPRO® Combination in Treating Relapsed Multiple Myeloma The U.S. FDA has approved the combination of TECVAYLI® and DARZALEX FASPRO® for treating adults with relapsed/refractory multiple myeloma, signaling a significant advancement in therapy options.

FDA Grants Approval for TECVAYLI® and DARZALEX FASPRO® Combination in Treating Relapsed Multiple Myeloma #United_States #San_Diego #Halozyme #DARZALEX #TECVAYLI

【J&Jの4剤併用療法、移植不適格の新規診断多発性骨髄腫で米国承認】

ジョンソン・エンド・ジョンソン（J&J）は、DARZALEX FASPRO（ダラツムマブ／ヒアルロニダーゼ）を含む4剤併用療法（D-VRd）が、移植不適格の新規診断多発性骨髄腫において米国FDAの承認を受けたと発表した 。

#多発性骨髄腫
#DARZALEX
#FDA承認

✨ #ASH25 : Résultats sans précédent de l'étude #MajesTEC_3 : #Tecvayli associé à #Darzalex Faspro pourrait devenir un nouveau standard dès la deuxième ligne chez les patients atteints de #MyélomeMultiple 🩸 en R/R
www.zonebourse.com/actualite-bo...

Darzalex Approval Marks Significant Milestone for High-Risk Smoldering Multiple Myeloma Treatment Darzalex has received regulatory approval for delaying progression in high-risk smoldering multiple myeloma, revolutionizing patient care.

Darzalex Approval Marks Significant Milestone for High-Risk Smoldering Multiple Myeloma Treatment #Japan #Johnson_&_Johnson #Tokyo #Multiple_Myeloma #DARZALEX

Hematology Weekly News – July 21st 2025 🔬🧬 Hematology Updates: CAR-T Hits 75% ORR, Blenrep FDA Hurdle, Columvi Rejected and More From CAR-T success in DLBCL to […] The post Hematology Weekly News – July 21st 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Hematology Weekly News – July 21st 2025 #News #AML #bloodcancer #CAR_T #Darzalex Comment below!

Johnson & Johnson’s Darzalex gets EU approval for smouldering myeloma Investing.com -- Johnson & Johnson (NYSE:JNJ) announced Wednesday that the European Commission has approved its Darzalex subcutaneous formulation as a monotherapy for adults with high-risk smouldering multiple myeloma. This marks the first approved treatment for this patient population, addressing an unmet clinical need for those with the asymptomatic intermediate disease state where abnormal cells can be detected in bone marrow. Professor Meletios A. Dimopoulos of the National and Kapodistrian University of Athens School of Medicine noted that 50 percent of high-risk patients progress to active multiple myeloma within two years, and the approval offers potential to change this trajectory. The approval was based on the Phase 3 AQUILA study, which showed patients receiving Darzalex had significantly improved progression-free survival compared to those under active monitoring. At 60 months, 63.1 percent of patients in the Darzalex arm remained alive and progression-free versus 40.8 percent in the monitoring arm. Overall survival was also extended with Darzalex, with 5-year survival rates of 93.0 percent compared to 86.9 percent for active monitoring. Patients receiving the drug saw a higher overall response rate of 63.4 percent versus 2.0 percent with monitoring. The safety profile was consistent with previous studies, with Grade 3/4 treatment-emergent adverse events occurring in 40.4 percent of treated patients compared to 30.1 percent of monitored patients. The most common Grade 3/4 adverse event was hypertension. Ester in ’t Groen, EMEA Therapeutic Area Head Haematology at Johnson & Johnson Innovative Medicine, said eligible patients no longer have to wait for progression without active treatment, instead having the option to intercept the disease with therapeutic intervention. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. ProPicks AI are 6 model portfolios created by Investing.com which identify the best stocks for investors to buy now. The stocks that made the cut could produce monster returns in the coming years. Is JNJ one of them?

Click Subscribe #JohnsonAndJohnson #Darzalex #Myeloma #CancerTreatment #Healthcare

Hematology Weekly News – July 21st 2025 🔬🧬 Hematology Updates: CAR-T Hits 75% ORR, Blenrep FDA Hurdle, Columvi Rejected and More From CAR-T success in DLBCL to […] The post Hematology Weekly News – July 21st 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Hematology Weekly News – July 21st 2025 #News #AML #bloodcancer #CAR_T #Darzalex Comment below!

Hematology Weekly News – July 21st 2025 🔬🧬 Hematology Updates: CAR-T Hits 75% ORR, Blenrep FDA Hurdle, Columvi Rejected and More From CAR-T success in DLBCL to […] The post Hematology Weekly News – July 21st 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Hematology Weekly News – July 21st 2025 #News #AML #bloodcancer #CAR_T #Darzalex Comment below!

#johnson-johnson #darzalex #anjus-worldwide #medical-device #oncology #cancer-treatment #pharmaceutical-industry #medical-device-industry #financial-reporting #quarterly-earnings #earnings-beat #sales-forecast #oncology-drug #growth-forecast #healthcare-industry

Johnson & Johnson beats profit estimates on strong Darzalex, medtech sales By Michael Erman (Reuters) -Johnson & Johnson reported second-quarter profit and raised its full-year sales forecast by around $2 billion on Wednesday as strong demand for its cancer drug, Darzalex, and strength in its medical device business helped it beat Wall Street expectations. On an adjusted basis, the drug and medical device maker earned $2.77 per share for the quarter, above analysts’ expectation of $2.68 per share, according to data compiled by LSEG. Sales in the quarter were $23.74 billion, above analysts’ expectation of $22.84 billion. The company said it now expects full-year sales in the range of $93.2 billion to $93.6 billion, up from its April forecast of $91 billion to $91.8 billion. Analysts on average had estimated sales of $91.5 billion for the year. It cited strong operational performance in the quarter as well as the stronger dollar for the increase. J&J (NYSE:JNJ) said in April that it was expecting $400 million in costs related to tariffs, mostly in the company’s medical device business, starting from the second quarter. Chief Financial Officer Joseph Wolk said in an interview that the company had now reduced that estimate to $200 million due to the pause on U.S. tariffs on China and other retaliatory tariffs. "We were able to absorb that and still raise our EPS guidance by 25 cents on the year," Wolk said. He said the company was not ready to forecast the impact of tariffs on 2026. "It’s such a fluid environment that we’ll just have to wait and see," he said. On an adjusted basis, J&J expects to earn $10.80 to $10.90 per share in 2025, compared with its previous forecast of $10.50 to $10.70 per share. Darzalex, a blood cancer therapy launched in 2015, brought in second-quarter sales of $3.54 billion, compared with analysts’ expectation of $3.38 billion. With JNJ making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed JNJ alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including JNJ, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is JNJ poised for similar growth? Don't miss the opportunity to find out.

Click Subscribe #JohnsonAndJohnson #Darzalex #Medtech #Pharma #Healthcare

New data reinforce daratumumab as standard of care for multiple myeloma - PharmaTimes Long-term survival projections suggest improved outcomes for patients

#Haematology #Oncology #daratumumab #multiplemyeloma #JanssenCilag #JnJInnovativeMedicine #subcutaneousDARZALEX #DARZALEX #daratumumab #PERSEUSclinicaltrial #CEPHEUSclinicaltrial #daratumumabVRd #VRdwithoutdaratumumab #PERSEUSregimen #daratumumabVRdwithmaintenancetherapy
zurl.co/1ZoEc

European Commission Greenlights Subcutaneous DARZALEX® Treatment for Newly Diagnosed Multiple Myeloma Patients The European Commission has approved a new treatment regimen involving subcutaneous DARZALEX®, offering hope to patients with newly diagnosed multiple myeloma.

European Commission Greenlights Subcutaneous DARZALEX® Treatment for Newly Diagnosed Multiple Myeloma Patients #None #Halozyme #Multiple_Myeloma #DARZALEX

DARZALEX: Pioneering Changes in Multiple Myeloma Treatments with Strong Market Position DARZALEX has become a dominant player in multiple myeloma treatment. This article explores its considerable efficacy, expanding market presence, and competitive landscape.

DARZALEX: Pioneering Changes in Multiple Myeloma Treatments with Strong Market Position #None #Multiple_Myeloma #DARZALEX #Janssen

Exploring the Growth Potential of the Multiple Myeloma Market: Trends and Forecasts for the Next Decade The multiple myeloma market is poised for significant growth over the next decade, driven by rising incidences and advancements in therapies such as CAR-T cell treatments.

Exploring the Growth Potential of the Multiple Myeloma Market: Trends and Forecasts for the Next Decade #None #CAR-T_therapy #Multiple_Myeloma #DARZALEX

Johnson & Johnson dépasse les attentes du quatrième trimestre Principaux renseignements Johnson & Johnson a dépassé les attentes avec ses résultats du quatrième trimestre, annonçant un chiffre d’affaires de 22,5 milliards de dollars (21,6 milliards d’euros) et un bénéfice par action ajusté de 2,04 dollars. Ce succès…

Johnson & Johnson dépasse les attentes du quatrième trimestre #JohnsonEtJohnson #RésultatsFinanciers #QuatrièmeTrimestre #ChiffreDaffaires #Darzalex